Your cutting-edge expert with the resources to manage your pharmacy program effectively, contain cost, and be accountable for the results. We are the next generation; we are the solution.
Drug Trends to Watch, Actions to Consider by Robert Kordella, RPh, MBASenior Vice President and Chief Clinical Officer DIABETES Rising prescription costs related to the
Excelsior’s Opinion on So-Called “Vision Enhancement Products” by Robert Kordella, RPh, MBA, Chief Clinical Officer Three products have come to market recently that are being
Humira Savings on the Horizon? by Robert Kordella, RPh, MBA, Chief Clinical Officer In 2021, Humira (adalimumab) amassed $21 billion in sales in the U.S.
Pharmacy renegotiation through Excelsior Solutions Annual Pharmacy Savings of $6.3M (23%
Using Data to Identify Fraudulent Claims Pharmacy Reimbursement of $26,000 Challenge
Opioid Case Study Annual Savings of $192,000 Challenge Member filling pain
With increasing specialty drug costs, pharmacy benefit managers,health plans and industry experts often tout the use of biosimilarsas a strategy to lower cost. In 2013,
As you may recall, back in March of this year, Eli Lilly announced that they would begin to manufacture and sell an authorized generic version
The news that the FDA approved the first A-rated (meaning that pharmacists may freely substitute it without physician approval) generic form of Advair Diskus on
Hello everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. ICER released a Final Evidence Report assessing the comparative clinical effectiveness and value
Hello everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. ICER has published its latest report on Unsupported Price Increases (UPI) of prescription
Hello, everyone, and welcome to this edition of Excelsior Solutions’ ICER Update. Here is this week’s ICER recap: ICER has published its latest report on
© Copyright 2019 Excelsior Solutions • Privacy Policy • All Rights Reserved